AU2023411346A1 - Amylin receptor agonists - Google Patents

Amylin receptor agonists

Info

Publication number
AU2023411346A1
AU2023411346A1 AU2023411346A AU2023411346A AU2023411346A1 AU 2023411346 A1 AU2023411346 A1 AU 2023411346A1 AU 2023411346 A AU2023411346 A AU 2023411346A AU 2023411346 A AU2023411346 A AU 2023411346A AU 2023411346 A1 AU2023411346 A1 AU 2023411346A1
Authority
AU
Australia
Prior art keywords
receptor agonist
compound
amylin receptor
amylin
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023411346A
Other languages
English (en)
Inventor
Cecilie Mia JØRGENSEN
Thomas Kruse
Jesper F. Lau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US18/512,512 external-priority patent/US12116388B2/en
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2023411346A1 publication Critical patent/AU2023411346A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2023411346A 2022-12-22 2023-12-21 Amylin receptor agonists Pending AU2023411346A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22215958.4 2022-12-22
EP22215958 2022-12-22
US18/512,512 2023-11-17
US18/512,512 US12116388B2 (en) 2022-12-22 2023-11-17 Amylin receptor agonists
PCT/EP2023/087353 WO2024133739A1 (en) 2022-12-22 2023-12-21 Amylin receptor agonists

Publications (1)

Publication Number Publication Date
AU2023411346A1 true AU2023411346A1 (en) 2025-07-24

Family

ID=89542238

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023411346A Pending AU2023411346A1 (en) 2022-12-22 2023-12-21 Amylin receptor agonists

Country Status (12)

Country Link
EP (1) EP4638480A1 (https=)
JP (1) JP2025542410A (https=)
KR (1) KR20250127104A (https=)
CN (1) CN120435491A (https=)
AU (1) AU2023411346A1 (https=)
CL (1) CL2025001805A1 (https=)
CO (1) CO2025008319A2 (https=)
IL (1) IL321586A (https=)
JO (1) JOP20250144A1 (https=)
MX (1) MX2025007124A (https=)
TW (1) TW202428309A (https=)
WO (1) WO2024133739A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008006A1 (en) 1992-09-30 1994-04-14 Zymogenetics, Inc. Human calcitonin receptor
ES2401965T3 (es) 2009-02-19 2013-04-25 Novo Nordisk A/S Modificación de Factor VIII
JP6121992B2 (ja) 2011-06-10 2017-04-26 ノヴォ ノルディスク アー／エス ポリペプチド
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物

Also Published As

Publication number Publication date
TW202428309A (zh) 2024-07-16
KR20250127104A (ko) 2025-08-26
CN120435491A (zh) 2025-08-05
EP4638480A1 (en) 2025-10-29
CO2025008319A2 (es) 2025-07-17
CL2025001805A1 (es) 2025-09-26
MX2025007124A (es) 2025-07-01
JP2025542410A (ja) 2025-12-25
IL321586A (en) 2025-08-01
WO2024133739A1 (en) 2024-06-27
JOP20250144A1 (ar) 2025-06-16

Similar Documents

Publication Publication Date Title
US12054528B2 (en) Co-agonists of the GLP-1 and amylin receptors
TWI810606B (zh) Gip/glp1共促效劑化合物
US10604555B2 (en) GIP derivatives and uses thereof
EP3068421B1 (en) Selective pyy compounds and uses thereof
AU2021374823B2 (en) Glp-1 prodrugs and uses hereof
EP4185607A1 (en) Co-agonists at glp-1 and gip receptors suitable for oral delivery
US9988430B2 (en) Stable GLP-1 based GLP-1/glucagon receptor co-agonists
WO2023139187A1 (en) Glp-1/gip receptor co-agonist prodrugs and uses thereof
US12116388B2 (en) Amylin receptor agonists
AU2023411346A1 (en) Amylin receptor agonists
JP7755031B2 (ja) Ｇｌｐ－１、ｇｉｐ、およびアミリン受容体の三重作動薬
EA049130B1 (ru) Коагонисты рецепторов glp-1 и gip, подходящие для пероральной доставки